Appears on
Articles2
Despite chaos and churn, FDA decisions hold mostly steady in H1 2026
Significant leadership instability at the FDA—compounded by continued workforce attrition—led to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has been catching up of late.
0
FDA News4d agoFDA freezes CRL trove as ‘radical transparency’ push hits speedbump
An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”
0
FDA News21h ago